Details for Patent: 8,765,813

Title:	Use of treprostinil to treat and prevent ischemic lesions
Abstract:	The present disclosure relates to novel methods for using treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The disclosure also relates to kits for treatment and/or prevention of ischemic lesions, which include an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Wade; Michael (Chapel Hill, NC), Jeffs; Roger (Chapel Hill, NC), Roscigno; Robert (Chapel Hill, NC), Strootman; Deborah (Tucson, AZ), Bronstein; Kathryn (Jupiter, FL)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Filing Date:	Dec 16, 2004
Application Number:	11/012,723
Claims:	1. A method for treating peripheral ischemic lesions on the skin of a subject, comprising administering to a subject in need thereof an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is an inhaled form of treprostinil or an oral form of treprostinil. 2. The method of claim 1, wherein the ischemic lesions are caused by at least one of scleroderma, Buerger's disease, Raynaud's disease and Raynaud's phenomenon. 3. The method of claim 1, wherein the ischemic lesions comprise digital ischemic lesions. 4. The method of claim 3, wherein the digital ischemic lesions comprise finger ulcers and/or necrotic lesions. 5. The method of claim 1, wherein the ischemic lesions are caused by systemic sclerosis. 6. The method of claim 3, wherein pain associated with the digital ischemic lesions in the subject is reduced. 7. The method of claim 1, wherein said administering comprises administering a pharmaceutically acceptable salt of treprostinil. 8. The method of claim 1, wherein the subject is a human being. 9. The method of claim 1, wherein said administering is performed subcutaneously. 10. The method of claim 1, wherein said administering is performed by continuous subcutaneous infusion. 11. The method of claim 1, wherein said administering is performed intravenously. 12. The method of claim 1, wherein said administering is performed orally. 13. The method of claim 1, wherein said administering is performed by inhalation. 14. The method of claim 1, wherein the effective amount is at least 1.0 ng/kg of body weight/min. 15. The method of claim 1, wherein the ischemic lesions are caused by systemic sclerosis, wherein the ischemic lesions comprise digital ischemic lesions, wherein said administering is continuous administration and wherein said administering promotes healing of at least one of the digital ischemic lesions, and reduces the development of new digital ischemic lesions. 16. A method for reducing pain associated with peripheral ischemic lesions comprising administering to a subject in need thereof an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is inhaled form of treprostinil or and oral form of treprostinil. 17. The method of claim 16, wherein the ischemic lesions comprise digital ischemic lesions. 18. The method of claim 2, wherein the subject is a human being with Buerger's disease that does not improve with smoking cessation. 19. The method of claim 1, wherein said administering is performed by continuous subcutaneous infusion by an infusion pump. 20. The method of claim 5, wherein said administering comprises orally administering to the subject an oral formulation comprising diethanolamine salt of treprostinil. 21. The method of claim 20, wherein said ischemic lesions comprise digital ischemic lesions. 22. The method of claim 21, wherein said administering promotes the healing of at least one of the digital ischemic lesions, and reduces the development of new digital ischemic lesions. 23. The method of claim 12, wherein said administering comprises administering to the subject an oral formulation comprising diethanolamine salt of treprostinil. 24. The method of claim 23, wherein said formulation is in a form selected from the group consisting of tablets and capsules. 25. The method of claim 16, wherein said administering comprises administering orally to the subject an oral formulation comprising diethanolamine salt of treprostinil. 26. A method of treating critical limb ischemia comprising administering to a subject in need thereof an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, wherein said derivative is an inhaled form of treprostinil or an oral form of treprostinil. 27. The method of claim 26, wherein said administering reduces rest pain associated with the critical limb ischemia in the subject. 28. The method of claim 26, wherein said administering results in healing ischemic lesions in the subject. 29. The method of claim 28, wherein said ischemic lesions comprise digital ischemic lesions. 30. The method of claim 29, wherein the digital ischemic lesions comprise finger ulcers and/or necrotic lesions. 31. The method of claim 26, wherein said administering comprises administering a pharmaceutically acceptable salt of treprostinil. 32. The method of claim 26, wherein said administering is performed subcutaneously. 33. The method of claim 26, wherein said administering is performed by continuous subcutaneous infusion. 34. The method of claim 26, wherein said administering is performed intravenously. 35. The method of claim 26, wherein said administering is performed orally. 36. The method of claim 35, wherein said administering comprises administering to the subject an oral formulation comprising diethanolamine salt of treprostinil. 37. The method of claim 35, wherein said formulation is in a form selected from the group consisting of tablets and capsules. 38. The method of claim 26, wherein said administering is performed by inhalation. 39. The method of claim 26, wherein the effective amount is at least 1.0 ng/kg of body weight/min. 40. The method of claim 26, wherein said administering is performed by continuous subcutaneous infusion by an infusion pump. 41. The method of claim 26, wherein the subject is a human being.